Device Trial Radar · NCT02750501
Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study
Last checked: Nov 20, 2026Latest source record: Aug 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Jul 20, 2016
Primary completion
Mar 30, 2017
Study completion Mar 30, 2017
Sponsor
- Lead sponsor
- Alcresta Therapeutics, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Cystic Fibrosis Foundation
- First posted
- Apr 25, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 4 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Protocol 0000498: Multicenter, open label study to evaluate the effect of sustained RELiZORB (immobilized lipase) cartridge use during enteral feeding on fat absorption, as well as safety and tolerability of sustained RELiZORB use, in patients with cystic fibrosis and exocrine pancreatic insufficiency.
Conditions
- Cystic Fibrosis
Interventions
RELiZORB (immobilized lipase) cartridgeDevice
Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
Impact Peptide 1.5Other
Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA)Time frame: Day 0 to Day 90
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Joe DiMaggio Children's Hospital / Memorial Healthcare System
Hollywood, Florida
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.